A Multicenter, Open-Label, Long-Term Study to Evaluate the Efficacy and Safety of LY2439821 in Japanese Patients with Moderate-to-Severe Psoriasis
Phase 4
- Conditions
- Psoriasis
- Registration Number
- JPRN-jRCT2080221846
- Lead Sponsor
- Eli Lilly Japan K.K.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
male or female patients aged 20 years or older who have the following:
Chronic Ps based on a confirmed diagnosis for at least 6 months prior to baseline (Week 0; Visit 2), a PASI score no less than 12, an sPGA score of no less than 3, and have no less than 10% BSA involvement at both Screening (Visit 1) and baseline (Week 0; Visit 2)
Are candidates for phototherapy and/or systemic therapy
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method